NEWS

For our visitors who seek the latest industry news and updates to keep abreast with the goings-on of the business on a global scale, Pharmaceutical Industry portal grants a dynamic and diverse feed of news items.

news

Oasmia Pharmaceutical and Karo Pharma have entered into an agreement concerning Karo Pharma’s cancer project KB9520, which has shown promising results in pre-clinical models for a number of different types of cancer. Oasmia acquires the project and strengthens its oncology project portfolio. Karo Pharma receives 3,080,000 newly issued shares as…

news

Lexicon reports positive top-line results in phase 2 dose-ranging study for sotagliflozin in patients with type 1 diabetes. Lexicon pharmaceuticals inc - trial met its primary endpoint. Lexicon pharmaceuticals inc says sotagliflozin was generally well tolerated in study. Lexicon pharmaceuticals inc - sanofi is expected to commence phase 3 clinical…

news

Can-Fite signs distribution deal for liver cancer drug CF102 in South Korea. Can fite biopharma says signed a distribution agreement with Chong Kun Dang Pharmaceuticals for exclusive right to distribute CF102. Deal provides for up to $3 million in upfront and milestone payments & a percentage rate of royalty payments…

news

Eli Lilly & Co. on Tuesday reported higher revenue, boosted by new drugs, but lower profit on higher costs. Shares of Lilly, down 5.4% over the past three months, fell 2.8% to $75.40 as results missed expectations. Chief Executive John Lechleiter said growth was led by recently-approved drugs. Recently released…

news

Merck & Co has won U.S. approval to market its immunotherapy Keytruda for use in previously untreated lung cancer patients two months ahead of schedule, making it the only such drug cleared for first-line treatment. The green light from the Food and Drug Administration (FDA), announced by the U.S. drugmaker…

news

Atyr Pharma receives FDA fast track designation for Resolaris to treat facioscapulohumeral muscular dystrophy (FSHD). Atyr Pharma Inc - expects to report data from three phase 1B/2 clinical programs for Resolaris in December 2016.   Source : reuters.com

news

Preclinical research demonstrates Peregrine Pharmaceuticals' PS-targeting antibodies enhance the anti-tumor activity of PD-l1 checkpoint inhibitors in model of Triple Negative Breast Cancer (TNBC). Peregrine Pharma- Experiments demonstrate that PS expression is upregulated on cancer cells following chemotherapy, radiation or photodynamic therapy.   Source : reuters.com

news

Medica Nord subsidiary Natumin Pharma AB has sold a pharmaceutical and trademark registration in respect Ecomer for the Polish market. In connection with this, the companies have signed a three year exclusive contract manufacturing of the product. This means that Medica Nord strengthens its presence in Poland. The parties have…

news

PharmaMar has announced the opening of a new affiliate in Austria with the aim of reinforcing the presence of the Company within Europe, one of the world's leading oncology markets. As Luis Mora, Managing Director at PharmaMar´s Oncology Business Unit, explains “the opening of this affiliate is part of our…

news

The Indian drug regulators, who were grappling with issues of quality, have a new beast to deal with — illegal export of drugs through repackaging by third party sources, a menace that adds to the growing number of quality issues for the drug industry. Mumbai-based Wanbury Ltd, one of the…